The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer: Validation using the mAb 12G4

Ovarian cancer has the highest mortality rate among gynecologic malignancies. The monoclonal antibody 12G4 specifically recognizes the human Müllerian inhibiting substance type II receptor (MISRII) that is strongly expressed in human granulosa cell tumors (GCT) and in the majority of human epithelia...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:MAbs
Main Authors: Kersual, Nathalie, Garambois, Véronique, Chardès, Thierry, Pouget, Jean-Pierre, Salhi, Imed, Bascoul-Mollevi, Caroline, Bibeau, Frédéric, Busson, Muriel, Vié, Henri, Clémenceau, Béatrice, Behrens, Christian K, Estupina, Pauline, Pèlegrin, André, Navarro-Teulon, Isabelle
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2014
Assuntos:
Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623115/
https://ncbi.nlm.nih.gov/pubmed/25517316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.29316
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares